What food firms are developing for GLP-1 weight regain
Nestlé and the US-based Robard Corporation have developed products aimed at people stopping GLP-1 weight-loss drugs, according to reporting by FoodNavigator on 2 October 2026. Their focus is appetite control after treatment, as food businesses consider how to respond to weight regain.
Nestlé has developed proprietary ingredient combinations intended to suppress appetite in people coming off the medicines. Robard’s product, a drink called Biocare2, is also aimed at reducing appetite after GLP-1 use, FoodNavigator reported.
Those descriptions establish the products’ intended purpose, not their effectiveness. The report provides no clinical trial results, participant numbers or follow-up periods showing whether either approach helps people maintain their weight after stopping medication.
The commercial proposition extends beyond drinks or specialist ingredients. Food businesses could also offer recipes, meal suggestions and nutrition guidance, alongside apps or subscription services designed for people whose appetite increases after treatment ends.
For consumers, the important distinction is between a product marketed for post-treatment support and one demonstrated to prevent weight regain. The report does not establish whether these products are available in the UK or what they would cost.
Why appetite can return after GLP-1 treatment
GLP-1 medicines act on pathways involved in appetite and blood sugar regulation. Semaglutide, sold as Wegovy for weight management, mimics a naturally occurring hormone and can help people feel fuller and eat less.
Some users describe a reduction in persistent thoughts about food, often called “food noise”. When treatment stops, its appetite-suppressing effects can diminish. Maintaining a lower weight may then become harder, although that does not mean every person will regain the same amount.
Obesity is a chronic condition, rather than simply a short-term problem resolved by reaching a target weight. For some patients, ongoing medication forms part of its management. A food product intended to help with appetite should not therefore be assumed to replace the effects of a prescribed medicine.
The underlying causes of regain remain an active research subject, including work by a US team awarded $4 million to investigate GLP-1 weight regain. Understanding those mechanisms is a different task from identifying a commercial market for people leaving treatment.
What IGD and Argon & Co say about maintenance
Caroline Young, head of insights at the Institute of Grocery Distribution, told FoodNavigator that maintaining weight loss would remain the long-term goal. She argued that the food industry should make this easier for people who have stopped GLP-1 medicines, through both products and practical support.
Michel Savini, associate partner for life sciences at the consultancy Argon & Co, did not expect difficulties after stopping treatment to undermine the overall GLP-1 market. His expectation was that some users would leave treatment while the market became more differentiated.
Savini cited typical one-year discontinuation rates of between 36% and 65%, with rates towards the higher end among people without diabetes. Expressed as absolute numbers, that range would mean roughly 36 to 65 people stopping within a year for every 100 starting treatment in the populations described.
Those figures concern stopping medication, not regaining weight. FoodNavigator did not identify the underlying studies, their sizes or how discontinuation was defined, limiting how confidently the range can be applied to a particular patient group or to UK services.
Savini also argued that regain strengthens the case for continuing treatment. He described a shift from viewing the medicines as a finite course towards regarding them as long-term therapy.
How oral GLP-1 medicines could change demand
The next question is whether more acceptable forms of medication will reduce the number of people seeking an alternative after treatment. Savini suggested that pills could remove some practical and psychological barriers associated with injections, including needles and sharps disposal.
He also pointed to the familiarity of taking daily tablets indefinitely. That is a commercial assessment, however, rather than evidence in this report that oral treatment produces better long-term persistence. Separate coverage examines weight outcomes after switching from injections to an oral Wegovy formulation, a different question from what happens when medication ends altogether.
Pills would not remove every reason for stopping. Savini noted that gastrointestinal side effects remain a consideration and can be more pronounced with some oral treatments. The report does not provide comparative figures for individual medicines.
For maintenance products, the unresolved scientific question is whether any appetite benefit translates into less weight regained over time. Research on support after stopping weight-loss injections is relevant to that wider challenge, but cannot establish the effectiveness of the particular products described here. FoodNavigator gave no timetable for clinical results addressing that question.
